Drug Profile


Alternative Names: NEO-101; NEO-102; NPC-1C

Latest Information Update: 15 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neogenix Oncology
  • Developer Duke University Medical Center; H. Lee Moffitt Cancer Center and Research Institute; Johns Hopkins Medical Institutions; Montefiore Medical Center; National Cancer Institute (USA); Precision Biologics; University of North Carolina; University of Texas Southwestern Medical Center; Yale University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Neoplasm antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase-I/II trial in Pancreatic cancer and Colorectal cancer (Late-stage disease, Second-line therapy or greater) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Mar 2017 Precision Biologics completes a phase I/II trial in Pancreatic cancer and Colorectal cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT01040000)
  • 09 Feb 2016 Updated efficacy data from a phase II trial in Colorectal cancer released by Precision Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top